Business Context and Reporting Period
This Form 8-K, dated January 28, 2003, reports E. I. du Pont de Nemours and Company's (DuPont) earnings for the fourth quarter and full year ended December 31, 2002. The filing includes a Regulation FD disclosure of the earnings news release, detailing financial performance, segment results, and outlook for 2003.
Key Financial Metrics
Revenue and Profit
- Consolidated Sales (4Q 2002): $5.68 billion (up 9% vs. 4Q 2001).
- Segment Sales (4Q 2002): $6.34 billion (up 7% vs. 4Q 2001, excluding acquisitions/divestitures).
- Full-Year 2002 Consolidated Sales: $24.01 billion (down 3% vs. 2001).
- Net Income (4Q 2002): $350 million ($0.35 per share diluted).
- Net Income (Full-Year 2002): Loss of $1,103 million ($1.11 per share diluted), driven by a $2,944 million charge for the cumulative effect of a change in accounting principles (SFAS 142).
- Earnings Before Special Items (4Q 2002): $0.34 per share (vs. $0.12 in 4Q 2001).
- Earnings Before Special Items (Full-Year 2002): $2.00 per share (vs. $1.19 in 2001).
Cash Flow, Margins, and Debt
- EBITDA (Full-Year 2002): $4.38 billion (up 3% vs. 2001).
- EBIT (Full-Year 2002): $2.92 billion (up 14% vs. 2001).
- Dividends: $1.40 per share for the full year 2002.
- Debt/Liquidity: The filing text does not provide specific values for total debt, cash balances, or liquidity ratios. It notes a $21 million charge for the early extinguishment of $242 million in debentures.
Material Changes vs. Prior Period
- Pharmaceuticals Sale Impact: 4Q 2001 net income included a $3,817 million after-tax gain from the sale of DuPont Pharmaceuticals. This one-time gain significantly inflated 2001 comparables.
- Accounting Changes: Full-year 2002 results include a $2,944 million non-cash charge for goodwill impairment under SFAS 142, turning a reported profit into a net loss.
- Volume Growth: Worldwide segment sales volumes increased 7% in 4Q 2002 and 1% for the full year, offsetting price declines in several segments.
- Segment Performance:
- Performance Materials: Full-year ATOI increased 53% to $423 million due to volume growth and lower raw material costs.
- Textiles & Interiors: Full-year ATOI improved significantly to $216 million from a $70 million profit in 2001, driven by restructuring and lower costs.
- Electronic & Communication Technologies: Full-year sales declined 6% due to weak demand in electronics and telecommunications markets.
Guidance, Outlook, and Risks
Outlook for 2003
- Earnings Impact: Pension and other postretirement expenses are expected to negatively impact 2003 earnings per share by $0.34 to $0.39 compared to the prior year. These are non-cash expenses.
- Tax Rate: The estimated full-year base income tax rate for 2003 is 30%, down from a 32.4% average actual rate for 1998-2001.
- Q1 2003 Expectation: Earnings per share (before special items) are expected to be roughly similar to the prior year, barring significant world events or economic disruption.
Risks and Contingencies
- Equity Adjustment: Stockholders' equity will be reduced by approximately $2.5 billion after-tax due to a decline in the market value of pension assets (non-cash).
- Legal Reserves: The company increased reserves for Benlate litigation ($80 million in 4Q) and vitamins litigation ($50 million in full year).
- Market Conditions: Risks include macroeconomic environment, competitive pressures, raw material costs, and foreign currency exchange rates (notably an exchange loss of $63 million related to Argentine pesos).
Investor Verification Checklist
- Verify the impact of the $2,944 million goodwill impairment charge on the reported full-year net loss.
- Confirm the sustainability of the 7% volume growth in 4Q 2002 across key segments like Performance Materials and Safety & Protection.
- Assess the magnitude of the $2.5 billion pension asset decline and its effect on future cash contributions or equity.
- Monitor the realization of the projected 30% effective tax rate for 2003.
- Review the status of Benlate and vitamins litigation reserves for potential future adjustments.